The PML gene of acute promyelocytic leukemia (APL) encodes a cell-growth and tumor suppressor. PML localizes to discrete nuclear bodies (NBs) that are disrupted in APL cells, resulting from a reciprocal chromosome translocation t (15;17). Here we show that the nuclear localization of PML is also regulated by SUMO-3, one of the three recently identified SUMO isoforms in human cells. SUMO-3 bears similar subcellular distribution to those of SUMO-1 and -2 in the interphase nuclear body, which is colocalized with PML protein. However, both SUMO-2 and -3 are also localized to nucleoli, a region lacking SUMO-1. Immunoprecipitated PML protein bears SUMO-3 moiety in a covalently modified form, supporting the notion that PML is conjugated by SUMO-3. To determine the functional relevance of SUMO-3 conjugation on PML molecular dynamics, we suppressed SUMO-3 protein expression using a siRNA-mediated approach. Depletion of SUMO-3 markedly reduced the number of PML-containing NBa and their integrity, which is rescued by exogenous expression of SUMO-3 but not SUMO-1 or SUMO-2. The specific requirement of SUMO-3 for PML nuclear localization is validated by expression of SUMO-3 conjugation defective mutant. Moreover, we demonstrate that oligomerization of SUMO-3 is required for PML retention in the nucleus. Taken together, our studies provide first line of evidence showing that SUMO-3 is essential for PML localization and offer novel insight into the pathobiochemistry of APL.
Introduction
The cell nucleus is known to contain several highly organized domains (for a review see Scheer and Weisenberger, 1994) . One distinctive class of subnuclear domains, the PML nuclear body (NB), appears as distinct dots under the immunofluorescence microscopy. The PML gene was identified at the translocation breakpoint in acute promyelocytic leukemia (APL) cells that contain the chromosomal translocation t (15;17) (for reviews see He et al., 1999; Melnick and Licht, 1999) . Gene-targeted disruption of PML demonstrates that the PML protein functions as a growth and tumor suppressor in vivo and is important for multiple apoptotic pathways (Wang et al., 1998) . However, the mechanisms by which PML exerts its tumor-growth suppressive functions remain to be determined.
PML is covalently conjugated to small ubiquitin-like modifier 1 (SUMO-1) (Sternsdorf et al., 1997; Mu¨ller et al., 1998) . SUMO-1 is also conjugated to various proteins that localize to different cellular compartments. In the nucleus, it concentrates in the NB where, besides PML, it covalently modifies other NB proteins such as Sp100 (Sternsdorf et al., 1997) .
Protein-protein interaction is fundamental for orchestrating a variety of cellular activities ranging from cell division to plasticity. Reversible covalent modification of proteins is a widely used regulatory mechanism for modulating protein-protein interaction via transmitting biological signals (e.g. Jentsch and Pyrowolakis, 2000; Johnson, 2004) . In addition to modification with low molecular weight modifiers, such as phosphorylation, nucleotidylation and acetylation, ubiquitin is also a well-documented posttranslational protein modifier (e.g. Mishra et al., 2004) . Ubiquitinylation involves the covalent attachment of the C terminus of ubiquitin to the e-amino moiety of specific lysyl residues in modified proteins (e.g. Johnson, 2004; Mishra et al., 2004; Seeler and Dejean, 2003) .
To date, there are about 15 known ubiquitin-like proteins that have been shown to couple to other target protein molecules (e.g. Seeler and Dejean, 2003) . Among them, small ubiquitin-related modifier (SUMO) is the most studied modifier. Although it bears a low sequence homology (18%) to ubiquitin, its atomic structure is very similar to that of ubiquitin. There are at least three SUMO isoforms in mammalian cells, namely; SUMO-1, -2 and -3 (e.g. Desterro et al., 1999) and most recently identified SUMO-4 (Bohren et al., 2004; Guo et al., 2004) . SUMO-1 shows 47% homology at the protein level with SUMO-2 and -3, whereas SUMO-2 and -3 are 95% homologous (e.g. Mahajan et al., 1998) . SUMO-1 is more distinct, being only 45% identical with either of the other isoforms. Glycine 97 of SUMO is conjugated to a lysine in target proteins (Kamitani et al., 1998a; Tatham et al., 2001 ) utilizing activating and conjugating enzymes similar to those in the ubiquitin conjugation pathway (Matunis et al., 1996) . Similar to ubiquitinylation, covalent attachment of SUMO to its target proteins requires three or four enzymes, namely: (i) SUMO protease which cleaves the C terminus of the nascent SUMO to expose the C-terminal glycine residue; (ii) the heterodimeric SUMO-activating enzyme that separates the adenylation and thio-esterification functions into the SAE1 (Aos1 in yeast) and the SAE2 (Uba2 in yeast) subunits, respectively; (iii) Ubc9, a SUMOconjugating enzyme that ligates directly to its protein substrate, such as RanGAP1; and (iv) an E3-like SUMO ligase (e.g. Kamitani et al., 1998a; Tatham et al., 2001) .
Unlike the majority of ubiquitinated proteins, acceptors of SUMO-1 modifications are not targeted for degradation. In fact, SUMO-1 modification of certain substrates is also known to have implications on subcellular localization. The interaction of Ran GTPase-activating protein 1 (RanGAP1) with the Ran-GTP-binding protein 2 at the cytoplasmic face of the nuclear pore complex is dependent on SUMO-1 (Bloch et al., 1996; Mahajan et al., 1998) . Modification of the PML protein targets it to distinct NBs (e.g. Bloch et al., 1999; Zhong et al., 2000; Eskiw et al., 2003) and is required for Daxx recruitment to these structures (e.g. Ishov et al., 1999; Eskiw et al., 2003) .
To explore the functional specificity of conjugation of different SUMO isoforms to PML protein, we evaluated the subcellular distribution of three SUMO isoforms tagged with green fluorescence protein and using isoform specific antibodies. Our studies show that all three SUMO isoforms examined share similar but not identical nuclear localization that overlaps with that of PML. Since SUMO-3 is conjugated to PML, we examined the functional relevance of such conjugation and found the requirement for SUMO-3 modification on PML. Elimination of SUMO-3 by siRNA caused egress of PML from nucleus and disruption of PML body integrity. We further demonstrated the function of SUMO-3 modification is exerted by oligomerization. Given the hetero-genetic requirement of SUMO-1 and -3 for the stabilization of PML in the nucleus, we proposed that SUMO-1 acts as a SUMO-3 polymeric chain terminator.
Results

Dynamic distribution of three SUMO isoforms in interphase and mitotic cells
Previous studies suggest that SUMO-1 is primarily located at the NB of interphase cells and redistributed to the kinetochore and centrosome as the cell enters mitosis (e.g. Azuma et al., 2003) . To explore the subcellular distribution profiles of SUMO-2 and SUMO-3 relative to SUMO-1, we carried out immunocytochemical studies of HeLa cells transfected with GFP-SUMO-1, GFP-SUMO-2 and GFP-SUMO-3, respectively. Western blotting analysis using a GFP monoclonal antibody showed that transfected cells expressed SUMO-1, -2 and -3 proteins at the right size of comparable level ( Figure 1A) .
To better visualize the subcellular localization, we adopted a pre-extraction procedure that allows effective labeling of the kinetochore and centrosomal proteins while preserving the fine cyto-structure of mitotic cells (e.g. Yao et al., 1997) . As shown in Figure 1B , preextracted HeLa cells were stained with a GFP monoclonal antibody followed by a fluorescein-conjugated secondary antibody to visualize SUMO-1, -2 and -3 signals. In the interphase cells shown in Figure 1B (a) , GFP-SUMO-1 appears as 10 clearly resolved dots in the nucleus (green, arrow). The nuclear localization becomes readily apparent when the GFP-SUMO-1 image is merged with DAPI staining, where green spots are colocalized with DAPI staining ( Figure 1B (c) ). GFP-SUMO-2 appears as 14 clearly resolved dots in the nucleus (g, arrow). The nuclear localization becomes readily apparent when the GFP-SUMO-2 image is merged with DAPI staining, where green spots are colocalized with DAPI staining ( Figure 1B (i) ). Interestingly, some SUMO-2 spots appeared to localize to nucleolus ( Figure 1B (i) ; arrowhead). This was validated by its codistribution with B23, a nucleolar mark ( Figure  1C (b) ). The SUMO-3 staining in interphase cells resembles that of SUMO-2. After survey of 117 cells from each of three SUMO isoforms positively transfected cells, we concluded that exogenously expressed GFP-SUMO-2 and GFP-SUMO-3 are localized to the nucleolus. Figure 1 Dynamic distribution of GFP-tagged SUMO-1, -2 and -3 in HeLa cells. (A) Expression of exogenous SUMO isoforms in HeLa cells. Samples from GFP-transfected, GFP-SUMO-1, GFP-SUMO-2 and GFP-SUMO-3-transfected HeLa cells were prepared and separated on SDS-PAGE, blotted onto nitrocellulose, and probed by a GFP monoclonal antibody (JL-18). Numbers on the right are the molecular weight markers. Note that the GFP antibody recognizes GFP (25 kDa) and exogenously expressed GFP-SUMO-1/2/3 (36 kDa) proteins. Typical expression level of exogenous proteins in positively transfected cells is about two-fold higher than that of endogenous protein. (B) Subcellular localization of exogenously expressed SUMO-1, -2 and -3 proteins in interphase and mitotic cells. HeLa cells were transfected with GFP-SUMO-1, GFP-SUMO-2 and GFP-SUMO-3 as described under 'Materials and methods.' At 36 h after transfection, cells were extracted, fixed and processed for immunocytochemistry. We scored 117 interphase cells expressing different SUMO isoforms for nucleolus staining. In addition, we also provided quantitative numbers of mitotic cell staining. (a-c) Confocal images collected from one interphase HeLa cell doubly stained for GFP-SUMO-1 (SUMO-1, green), DAPI (DNA, blue) and their merged images. GFP stained the nucleus of interphase HeLa cells. Bar, 10 mm. (d-f) Confocal images collected from mitotic HeLa cell doubly stained for GFP-SUMO-1 (SUMO-1, green), DAPI (DNA, blue) and their merged images. GFP stained the sister chromatid (f, arrowheads) and spindle of anaphase HeLa cells in the merge (f). Bar, 10 mm. (g-i) Confocal images collected from one interphase HeLa cell doubly stained for GFP-SUMO-2 (SUMO-2, green), DAPI (DNA, blue) and their merged images. GFP stained the nucleus of interphase HeLa cells as a number of dots with some dots localized to the nucleolus in the merge (c, arrow). Bar, 10 mm. (j-l) Optical sections of images collected from one mitotic HeLa cell doubly stained for GFP-SUMO-1 (SUMO-1, green), DAPI (DNA, blue) and their merged images. GFP stained the sister chromatid (j and l, arrowheads) and midbody of anaphase HeLa cells in the merge (j and l, arrow). Bar, 10 mm. (m-o) Optical sections from confocal images collected from one interphase HeLa cell doubly stained for GFP-SUMO-3 (SUMO-3, green), DAPI (DNA, blue) and their merged images. GFP-SUMO-3 stained the nucleus of interphase HeLa cells as a number of dots with some dots localized to the nucleolus in the merge (c, arrow). Bar, 10 mm. (p-r) Optical images collected from one mitotic HeLa cell doubly stained for GFP-SUMO-3 (SUMO-3, green), DAPI (DNA, blue) and their merged images. GFP-SUMO-3 stained the sister chromatid as separate double dots (r, arrow) and spindle of anaphase HeLa cells in the merge. Distinct staining patterns of SUMO-2 and SUMO-3 in anaphase cells suggest possible substrate specificity between SUMO-2 and -3. Bar, 10 mm. (C) SUMO-2 and SUMO-3 but not SUMO-1 are localized to the nucleolus in interphase HeLa cells. HeLa cells were transfected with GFP-SUMO-1, GFP-SUMO-2 and GFP-SUMO-3 as described under 'Materials and methods.' At 36 h after transfection, cells were extracted, fixed and processed for immunocytochemistry. (a-c) Optical sections of cofocal merges collected from interphase HeLa cell triply stained for GFP-SUMO isoforms (SUMO, green), B23 (B23, red) and DAPI (DNA, blue). It is readily apparent that SUMO-2 and SUMO-3 are also localized to the nucleolus marked by B23. (b and c, arrow) . Bar, 10 mm SUMO-3 is essential for PML stability C Fu et al
The chromosomes and mitotic spindle form as the cell enters into mitosis. The distribution of SUMO-1 is reminiscent of centromere and mitotic spindle, which is readily apparent as it is merged with DAPI staining ( Figure 1B (f) ). This is consistent with the literature (Azuma et al., 2003) . In mitotic cells, SUMO-2 staining appears as the dumb-bell shaped staining in anaphase cells. The staining of SUMO-2 is reminiscent sister chromatid labeling, which becomes apparent as it is merged with DAPI staining (Figure 1B (l) ). Careful examination also revealed the deposition of SUMO-2 at the midbody ( Figure 1B (l) , arrow) in addition to centromere-like staining ( Figure 1B (l) , arrowheads). The distribution of SUMO-3 in the mitotic cells was shown in Figure 1B (p-r). Similar to that of SUMO-2, SUMO-3 staining appears mainly on sister chromatids of anaphase cells ( Figure 1B (r) ; arrow). In addition, SUMO-3 displays as dots on the mitotic spindles. Thus, we conclude that SUMO-1, -2 and -3 display similar but not identical subcellular distribution profiles in interphase and mitotic cells.
SUMO-3, like SUMO-1 and -2, is mainly localized within the PML body in interphase cells It has been shown that PML is a substrate for SUMO-1 and that SUMOylation of PML is responsible for the NB targeting and retention of PML. To establish the subcellular distribution profiles of three SUMO isoforms relative to PML, we transfected three GFP-tagged SUMO constructs into HeLa cells, respectively, and probed for their localization in interphase cells relative to PML. As shown in Figure 2 , all three SUMO isoforms display NB-like staining profile (a, a 0 and a 00 ). This became apparent when each of the SUMO isoform staining is merged with respective PML staining in interphase nuclei (d, d 0 and d 00 ). Remarkably, virtually no SUMO-1 is localized to nucleoli, compared to that of SUMO-2 and -3 (d 0 and d 00 ; arrows), suggesting that SUMO-2 and -3 may be conjugated to a somewhat different subset of protein targets than those of SUMO-1 in interphase cells. Immunocytostaining of endogenous SUMO isoforms with isoform specific antibody gave essentially the same profiles ( Figure 2B ). Triple staining of endogenous SUMO-1 along with exogenously expressed SUMO-2 and -3 validated the observation made with GFP-SUMO isoforms that all three SUMO isoforms are indeed codistributed to PML body, while SUMO-2 and -3 are also located to nucleoli ( Figure 2C ; arrow).
To test if endogenous SUMO-2/3 is conjugated with PML, we performed immunoprecipitation assays using interphase HeLa cell lysates incubated with PML and CENP-E control antibody, respectively. As shown in Figure 2D , the PML antibody pull down several PML reactive polypeptides ranging from 85 to 116 kDa (indicated by arrows). Western blotting with SUMO-3 antibody indicated that the 116 kDa form of PML is conjugated with SUMO-3, consistent with the literature (Tatham et al., 2001) . The 97 kDa polypeptide is an unconjugated form of PML and while the 67 kDa polypeptide is a proteolytic product of PML. Thus, we conclude that PML is SUMOylated by SUMO-3 isoforms in interphase cells. , similar to that shown in (a 00 ). A merge verifies colocalization of GFP-SUMO-3 to that of PML. Note the SUMO-3 is also localized to the nucleolus (d 00 , arrow). Bar, 10 mm. (B) Endogenous SUMO-2 and -3 isoforms are also localized to the nucleolus. HeLa cells were triply labeled with a mouse PML antibody and isoform specific SUMO rabbit antibodies, respectively, as described under 'Materials and methods.' (a-d) Confocal images collected from one HeLa cell triply stained for anti-PML antibody (PML, red), anti-SUMO-1 (SUMO-1, green), DAPI (DNA, blue) and their merged images. SUMO-1 labeling appears as a number of clearly resolved dots (b), similar to that shown in (a). A merge verifies colocalization of endogenous SUMO-1 to that of PML. Bar, 10 mm. (a 0 -d 0 ) Confocal images collected from one HeLa cell triply stained for anti-PML antibody (PML, red), anti-SUMO-2 (SUMO-2, green), DAPI (DNA, blue) and their merged images. SUMO-2 labeling appears as a number of clearly resolved dots (b 0 ), similar to that shown in (a 0 ). A merge verifies colocalization of SUMO-2 to that of PML. Note the SUMO-2 is localized to the nucleolus (d 0 , arrow). Bar, 10 mm. (a 00 -d 00 ) Confocal images collected from one HeLa cell triply stained for anti-PML antibody (PML, red), SUMO-3 antibody (SUMO-3, green), DAPI (DNA, blue) and their merged images. SUMO-3 staining appears as a number of clearly resolved dots (b 00 ), similar to that shown in (a 00 ). A merge verifies colocalization of SUMO-3 to that of PML. Note the SUMO-3 is also localized to the nucleolus (d 00 , arrow). Bar, 10 mm. (C) Three SUMO isoforms have similar but not identical distribution profile in the nucleus. HeLa cells were transfected with GFP-SUMO-2 and HA-SUMO-3. Fixed cells were labeled with a mouse SUMO-1 antibody and rabbit HA antibody as described under 'Materials and methods.' (a-d) Confocal images collected from one HeLa cell triply stained for three SUMO isoforms: anti-SUMO-1 (SUMO-1, red), GFP (GFP-SUMO-2, green), anti-HA (HA-SUMO-3, blue) and their merged images. A merge verifies essential colocalization of all three isoforms to the nuclear body. Note the SUMO-2 and -3 are also localized to the dot without SUMO-1 labeling (d, arrow). Bar, 10 mm. (D) SUMO-3 is conjugated onto PML protein. HeLa cells were extracted and subjected to immunoprecipitations by using polyclonal antibody to PML. Control immunoprecipitations were performed using a CENP-E rabbit IgG. Immunoprecipitates were analyzed by SDS-PAGE and immunoblotting using a PML and a SUMO-3 antibody, respectively. No tubulin was detected in either PML or CENP-E immunoprecipitates. Numbers on the left indicate the molecular weight (in kDa) SUMO-3 is essential for PML stability C Fu et al
Elimination of SUMO-3 destabilizes PML localization in the nucleus
In vitro biochemical studies have demonstrated that PML is modified by SUMO-1 and SUMO-2/3, although the functional significance of SUMO-2/3 conjugation has not been elucidated given the high similarity between SUMO-2 and -3 (e.g. Tatham et al., 2001) .
To investigate the possible influence of SUMO-3 conjugation on the localization of PML to the NB, we introduced RNA interference (RNAi) oligonucleotides to SUMO-3 by transfection into HeLa cells. To find an effective timing for knocking down SUMO-3 protein levels by using RNAi, we transfected HeLa cells with 100 nM oligonucleotides and collected cells at different intervals of post-transfection. As shown in Figure 3A , Western blot with a SUMO-3 antibody revealed that the RNAi oligonucleotide caused remarkable suppression of the SUMO-3 protein level 48 h after the transfection, whereas control cells treated with an irrelevant oligonucleotides (e.g. cyclophilin) express normal levels of SUMO-3. This suppression is relatively specific as it did not alter the levels of other proteins such as SUMO-1, SUMO-2, Daxx and b-tubulin.
Immunoblotting with a SUMO-3 antibody revealed that 100 nM SUMO-3 RNAi oligonucleotide caused a remarkable six to seven-fold suppression of SUMO-3 protein without altering the levels of other proteins such as tubulin and PML. As SUMO-3 synthesis in the B25% of untransfected cells with little or no oligonucleotide was unlikely to be markedly diminished, the observed six-to seven-fold inhibition at 100 nM must represent almost complete inhibition of SUMO-3 in 7573% of successfully transfected cells.
We next examined whether depletion of SUMO-3 protein alters localization of PML protein to the NB, and we treated HeLa cells with 100 nM RNAi and either a scrambled oligonucleotide or a control cyclophilin oligonucleotide, respectively. Careful examination of these SUMO-3-suppressed cells also revealed that both the number of PML NBs and the normalized pixel of PML nuclear staining were significantly reduced (Po0.01; Figure 3B ). We surveyed approximately 150 interphase cells, in which all PML bodies were in the Figure 3C , a summary from three different experiments show that the depletion of SUMO-3 resulted in significant reduction in PML bodies (472 per cell) compared to control group (1373 per cell; Po0.01). Quantitation of normalized pixel intensities shows that NB-bound PML levels are reduced to 2275% of their control values upon suppression of SUMO-3. Western blotting of PML from nuclear and cytoplasmic fractions confirmed that elimination of SUMO-3 resulted a redistribution of PML from the nuclear fraction to the cytosolic fraction (71.975.3% of control vs 25.377.9% of SUMO-3-suppressed cells as shown in Figure 3D ). Staining of other NB protein such as Sp100 revealed that Sp100 failed to retain its nuclear localization in SUMO-3-depleted cells (Zerenshki et al., unpublished observation), consistent with several earlier studies (e.g. Ishov et al., 1999) . Significantly, exogenously expression of SUMO-3 but not SUMO-1 rescues the defects associated with SUMO-3 knockdown ( Figure 3D ). However, overexpression of SUMO-2 only partially restores the phenotypic changes associated with SUMO-3 suppression, suggesting that possible functional specificity exists between SUMO-2 and -3 isoforms. Thus, we conclude that SUMO-3 is required for a stable organization of PML body in the nucleus.
To test the functional specificity of SUMO isoforms and whether elevation of SUMO-1 and -2 protein levels could rescue the phenotype seen in the SUMO-3-suppressed cells, we transfected HeLa cells with SUMO-3 siRNA oligonucleotides along with GFPtagged SUMO-1, -2 and -3, respectively. As shown in Figure 3D , quantitative analyses of PML protein contents in nuclear and cytoplasmic fractions demonstrated that exogenous expression of SUMO-3, but not SUMO-1 and -2, prevent the release of PML protein from nucleus into the cytoplasm in SUMO-3 siRNAtreated cells, supporting our notion that SUMO-3 is essential to stabilizes PML localization in the nucleus.
Conjugation of SUMO-3 to PML is essential for a stable nuclear localization of PML Since the conserved Gly residues adjacent to the Cterminal SUMO-3 are essential for its conjugation to PML (Tatham et al., 2001) , we sought to validate the requirement of SUMO-3 conjugation for PML nuclear localization. To this end, we expressed SUMO-3 mutant lacking the C-terminal DGG residues in HeLa cells by transfection. Western blotting analysis carried out using transfected HeLa cells showed that exogenously expressed GFP-SUMO-3 proteins (both wild type and DGG-deletion mutant) were about three times the level of endogenous SUMO-3 (data not shown). Microscopic examination revealed that the SUMO-3 deletion (XDGG) mutant is diffused throughout the nucleus ( Figure 4A (b) ). However, examination of these mutant SUMO-3-transfected cells revealed that the number of NBs marked by PML was significantly reduced (Po0.01), similar to those seen in SUMO-3-depleted cells by siRNA treatment ( Figure 3B ). We surveyed approximately 150 interphase cells in each preparation, from three different experiments in which NBs marked by PML were in the same focal plane. As shown in Figure 4B , expression of the SUMO-3 deletion mutant resulted in significant destabilization of PML body formation and/or maintenance in the nucleus (572, compared to 1774 of control; Po0.01), validating the outcome from our early SUMO-3 suppression experiment using siRNA ( Figure 3B ). Quantitative analysis of normalized pixel intensities shows that NB-bound PML levels are reduced to 2173% of their control values upon suppression of SUMO-3 (Po0.01). Therefore, we conclude that SUMO-3 conjugation is essential for a stable localization of PML in the nucleus.
It has been shown that SUMO modification on PML plays an important role in NB assembly. To validate whether SUMO-3 is directly conjugated to PML and the conjugation with SUMO-3 is sufficient for its NB localization, we generated two PML mutants that had two potential SUMOylation sites, Lys160 and Lys490, which were changed to Arg (Kamitani et al., 1998a) , and transfected the mutants and wild-type PML plasmids into HeLa cells, respectively. As show in Figure 5A (lanes 1 and 2), two distinct bands, migrating at 116 and 140 kDa, were identified with a GFP monoclonal antibody. However, the upper 140 kDa band disappeared upon mutation of Lys160 (lane 3), consistent with an earlier study (Kamitani et al., 1998b) . Probing the same strip with SUMO-3, but not SUMO-1, antibody marked the upper 140 kDa band from wild type and K490R PML expression samples, validating that mutation of Lys160 abolished conjugation of SUMO-3 to PML. The lower 116 kDa band reacting with the GFP antibody indicated the unmodified forms of PML were expressed equally well in both wild type and two mutants (lanes 1, 2 and 3). Thus, we conclude that SUMO-3 is conjugated to Lys160 on PML protein.
To test whether elimination of SUMO-3 conjugation to PML alters its localization to the nuclear body, we expressed wild type and mutant PML (both K160R and K490R) in HeLa cells. Expression of wild-type GFP-PML displayed a typical NB dot-like staining that is superimposed onto that of SUMO-3 ( Figure 5B (d) ), consistent with several earlier studies (e.g. Ishov et al., 1999; also Figure 2 ). However, expression of K160R mutant PML displayed a diffused nuclear localization in addition to the cytoplasmic distribution (e), suggesting that elimination of SUMO-3 conjugation destabilized the NB localization of GFP-PML. Careful examination of SUMO-3 staining revealed a general diffused distribution profile with a few nuclear dots (f, arrows), reminiscent of NB staining. The merged (h) image validated that SUMO-3 is no longer colocalized with K160R PML, consistent with the western blot study ( Figure 5A ), in which SUMO-3 was not conjugated to mutant K160R PML protein. To validate whether the K160R mutant alters the nuclear localization of other SUMO isoforms, GFP-K160R PML expressing cells SUMO-3 is essential for PML stability C Fu et al were stained with SUMO-1 and -2 antibody, respectively. Immunocytostaining indicated that SUMO-1 and -2 retained their NB distribution (j and n) while K160R PML is distributed throughout nucleus (i and m). The inability of K160R PML mutant to assemble and/or be retained at the NB suggests that conjugation of SUMO-3 to PML is required for its NB localization.
To validate the specificity of conjugation of SUMO-3 to lysine 160 on PML protein and its functional relevance, we expressed K490R mutant PML and tested for its subcellular distribution profile. In the mutant K490R expressing cells shown in (r), GFP-PML also appears as clearly resolved dots in the nucleus (green). The colocalization of K490R mutant with SUMO-3 at the NB becomes readily apparent in the merged image (u). Thus, we conclude that SUMO-3 is directly conjugated to PML via Lys160 and this conjugation is required for PML localization to the NB.
Oligomerization of SUMO-3 is essential for retention of PML protein in the nucleus
Although SUMO-2 and -3 share 50% sequence identity with SUMO-1, they are functionally distinct from SUMO-1 by several means. It has been shown that lysine 11 in SUMO-2 and -3 is required for poly-(SUMO) chain formation (Matunis et al., 1996) . However, it is unclear whether polymerization of SUMO-2 and -3 plays any role in PML nuclear localization. To test whether a stable nuclear localization of PML requires SUMO-3 oligomerization, we generated a polymerization-defective SUMO-3 (K11R) construct and transfected it into HeLa cells. Western blotting showed that both SUMO-2 (K11R) and SUMO-3 (K11R) proteins were expressed in great abundance at the right molecular weight ( Figure 6B ). Microscopic examination revealed that the SUMO-3 polymerization defective mutant (K11R) appears as diffused NB spots ( Figure 6C (b  0 ) ). Careful examination of these mutant SUMO-3-transfected cells revealed that the number of NBs marked by PML was significantly reduced, similar to those seen in SUMO-3-suppressed cells in siRNA treatment ( Figure 3B) . We surveyed Cultures of HeLa cells were either mock-transfected (scramble) or transfected with SUMO-3 siRNA oligonucleotide. 48 h post-transfection, the cells were homogenized and separated into nuclear and cytoplasmic fractions as described under 'Experimental procedures.' Equivalent amounts of proteins from the soluble and insoluble fractions were applied to SDS-PAGE. Following separation on 6-16% gradient SDS-PAGE and transblotted onto nitrocellulose membrane, the blots were probed with an anti-PML antibody and developed with an ECL kit. The PML signals were quantified using a PhosphorImager with values expressed as a percentage of total (soluble þ insoluble).
In some experiments, GFP-SUMO-1/2/3 plasmids were cotransfected with SUMO-3 siRNA to test whether expression of each of SUMO isoforms can rescue the phenotype seen in SUMO-3 siRNA. Although a typical expression of GFP-SUMO isoforms is two-fold higher than that of endogenous protein, GFP-SUMO-3 but not GFP-SUMO-1 and GFP-SUMO-2 rescued the phenotypic changes associated with SUMO-3 knockdown. The error bars represent s.e.; n ¼ 3 preparations SUMO-3 is essential for PML stability C Fu et al approximate of 150 interphase cells of each preparation, from three different experiments in which NBs marked by PML were in the same focal plane. As shown in Figure 5C , expression of the SUMO-3 polymerization defective mutant resulted in significant destabilization of PML body formation and/or maintenance in the nucleus (472 nuclear bodies/nucleus; compared to 1374 in control cells), validating the outcome from our early siRNA experiment and SUMO-3 conjugation-defective mutant (e.g. Figure 3B and Figure 4A ), respectively. Quantitation of normalized pixel intensities shows that nuclear body-bound PML levels are reduced to 1972% of their control values upon overexpression of SUMO-3 polymerization defective mutant. To explore if there is synergism between SUMO-3 and -2 hetero-oligomerzation, we cotransfected polymerization defective mutants of SUMO-2 and -3 into HeLa cells. Coexpression of these two mutants causes diffused PML staining throughout the nucleus. Quantitation of normalized pixel intensities shows that NB-bound PML levels are reduced to 1174% of their control values upon overexpression of SUMO-3 and -2 polymerization defective mutant. Therefore, we propose that functional conjugation of SUMO-3 to PML requires oligomerization of SUMO-3, which is essential for a stable localization of PML in the nucleus.
Discussion
We have carried out biochemical and cytological characterization of three different SUMO isoforms and examined the functional specificity of SUMO-3 conjugation on PML. The similar but not identical distribution profile of all three SUMO isoforms demonstrated in this study further suggest that SUMO isoforms exert functional specificity. However, the molecular basis for the localization of SUMO-2 and -3 to the nucleolus remains unclear. The codistribution of SUMO-3 with PML, together with the fact that suppression of SUMO-3 liberates PML from the NB, indicates that the modification of PML by SUMO-3 is required for a stable association of PML with the NB. Significantly, overexpression of SUMO-1 was unable to rescue the phenotype associated with SUMO-3 suppression, suggesting that distinct functional activity exists between the SUMO isoforms. In addition, we have illustrated the molecular basis of how SUMO-3 conjugates to PML. Our finding that oligomerization of SUMO-3 is required for PML retention in the nucleus demonstrates the importance of SUMO-3 modification in NB dynamics. Based on the sequence homology, the known SUMO isoforms can be divided into two groups in vertebrates: one including SUMO-1 while the other composed of SUMO-2, -3 and -4. The sequence divergence of SUMO-2/3 from SUMO-1 suggests a distinct role of conjugation with SUMO-2 and -3. Despite a considerable amount of research on SUMO-1, information regarding the functional specificities of SUMO-2 and -3 has been limited. Hints for distinct roles for SUMO-1 and -2 have emerged from investigations using mammalian cells transfected with SUMO-1 and -2 constructs in which distinct profiles of conjugated proteins were generated when analyzed by Western blotting (Vertegaal et al., 2004) . It has been demonstrated in in vitro studies that formation of polymeric chains of SUMO-2 and -3 on protein substrates such as PML and HDAC4 (e.g. Matunis et al., 1996) is required for efficient conjugation. The ability to form polymeric chains is unique for SUMO-2/3 and not shared by SUMO-1. Our studies demonstrate that oligomerization of SUMO-3 is conjugated to Lys160 and this conjugation is required for a stable NB-associated localization of PML, providing a functional link between SUMO-3 oligomerization and the NB retention of PML.
The PML NBs have offered a unique system for the elucidation of the biological role of SUMOylation since the major NB constituents such as PML and SP100 are SUMO-1-modified and their modification is essential for nuclear function (Mu¨ller et al., 1998; Ishov et al., 1999) . The functional relevance of SUMO modification on NB dynamics was suggested by the observation that trivalent arsenic leads to a dramatic increase in PML SUMO-3 is essential for PML stability C Fu et al SUMOylation (Mu¨ller et al., 1998; Zhu et al., 2002) , correlating with an increase in NB size in normal cells and the reaggregation of the NB derivatives in leukemic APL cells. Fractionation studies further showed that the bulk of the SUMO-modified PML resided in the insoluble NB-associated fraction (Mu¨ller et al., 1998) . Figure 5 Conjugation of SUMO-3 to Lys160 is required for the localization of PML to the nuclear body. (A) SUMO-3 is conjugated to Lys160 of PML. HeLa cells were transfected with mutant K160R and K490R PML cDNA construct, respectively. The transfected cells were collected 36 h after transfection and subjected to SDS-PAGE followed by immunoblotting. Upper two panels, immunoblots of GFP-PML and SUMO-3, respectively; middle panel, immunoblot against b-tubulin; lower two panels, immunoblots of SUMO-1 and SUMO-2/3, respectively; Lesser extents of SUMO-1 and SUMO-2/3 were conjugated onto endogenous PML as mutant GFP-PML (K160R) compete with endogenous PML. Transfection of wild-type GFP-PML plasmid was used as a control. Probing with SUMO-3 antibody showed that mutation of Lys160 to Arg abolished the SUMO-3 conjugation to GFP-PML. Numbers on the left indicate the molecular weight (in kDa). (B) Lys160 is required for PML to retain a stable NB localization. This set of optical images represents HeLa cells transfected with K160R and K490R mutant PML fused with GFP (green) and doubly stained for SUMO-1, -2 or -3 protein (red), DNA (blue) and their merged images. (a-d) Confocal images collected from HeLa cells triply stained for wild-type GFP-PML (PML[wt], green), SUMO-3 (red), DAPI (DNA, blue) and their merged images. Exogenous GFP-PML appears as a number of clearly resolved dots (b), similar to its endogenous protein (e.g. Figure 2A ). A merge verifies colocalization of GFP-PML to that of SUMO-3 at the nuclear body. Bar, 10 mm. Finally, the examination of PML À/À cells revealed the other normally NB-associated proteins (e.g. SP100, Daxx) become nuclear diffuse or mis-localized (Duprez et al., 1999; Zhong et al., 2000) , suggesting that PML constitutes the NB 'scaffold'. In fact, this was validated by 'add-back' experiments with wild-type PML and a mutant derivative in which the three SUMO acceptor lysines had been mutated (Kamitani et al., 1998b) . Similarly, re-addition of wild-type PML to PML À/À cells led to the re-recruitment of other NB proteins into PML-containing nuclear dots while the nonmodifiable PML mutant did not (Duprez et al., 1999; Zhong et al., 2000) , demonstrating the importance of SUMO modification. While these results suggest that proper NB formation requires SUMO-modified PML, the nature of SUMO species conjugation to PML protein in these studies was unclear. Our studies presented here provide the first evidence that SUMO-3 is conjugated to Lys160, a site that also implicates in SUMO-1 modification (e.g. Kamitani et al., 1998b) . The fact that the elimination of SUMO-3 conjugation of Lys160 abolishes the ability of PML to assemble and/or be retained at the NB indicates the importance of SUMO-3 modification. While we demonstrate the significance of these polymeric forms of SUMO-3 conjugated to PML, it remains elusive how oligomerization of SUMO-3 retain PML in the nucleus. One possibility is that poly-SUMOylated proteins may represent a more distinct signal to other proteins for recognition and binding, which enables them to form a macromolecular complex such as NB. Given the fact that SUMO-1 modification is required for PML retention in the NB (e.g. Kamitani et al., 1998b; Zhong et al., 2000) , it becomes plausible that SUMO-1 may act as a SUMO-3 polymeric chain terminator to conjugate PML for NB protein complex formation and/or stabilization. Certainly, the experimental evidence supporting this notion requires monitoring the PML molecular dynamics in SUMO conjugation-manipulated system at single molecule scale.
Mounting evidence supports the role of SUMO-1 modification of PML in the biogenesis of NB (e.g. Zhong et al., 2000) . Interestingly, expression of SUMO-3 nonconjugatable PML (K160R) did not abolish the NB localization of SUMO-1 and -2 despite the fact that both the number of NBs per cell and the labeling intensity of SUMO-1 and -2 per NB are significantly reduced ( Figure 5B ). It seems that the exogenously expressed PML mutant (K160R) did not compete off endogenous wild-type PML and the residual NB-bound wild-type PML protein is sufficient to provide foci with which NBs can be assembled and SUMO-1 conjugation to other NB proteins is retained. Given the fact that all three SUMO species can be conjugated to PML, future studies will be directed at delineating the precise and respective functions and regulation of the modifications exerted by different SUMO isoforms. This will involve simultaneous manipulation of PML and individual SUMO isoform in an expression controllable system.
Although SUMO-2 and -3 are 96% identical, it was surprising that overexpression of SUMO-2 did not completely restore the phenotypic change associated with SUMO-3 suppression to the comparable level. Thus, the 3-amino-acid difference in the N-terminal region appears to contribute the biochemical and functional specificity between SUMO-2 and -3. Whether this specificity is due to different secondary structures of the two modifiers in this region or specific amino-acid interactions with the conjugation enzyme such as Ubc9 remains to be determined. Recently, two studies have identified the existence of SUMO-4 that encodes a 95-amino-acid protein with an 86% amino-acid homology with SUMO-2/3 (Bohren et al., 2004; Guo et al., 2004) . In contrast to SUMO-2/3, which is highly expressed in all of the tissues examined, SUMO-4 mRNA was detected mainly in the kidney. It would be of great interest to elucidate the subcellular localization and substrates of SUMO-4. Such information will aid in delineating the structure-functional relationship of SUMO protein family.
Taken together, we demonstrated that SUMO-3 is conjugated to PML via Lys160 and this conjugation is essential for its NB localization. The finding that suppression of SUMO-3 conjugation to PML protein and perturbation of SUMO-3 oligomerization disrupt assembly of PML to the NB demonstrates the importance of SUMO-3 modification in NB dynamics.
Materials and methods
Cell culture
HeLa cells, from American Type Culture Collection (Rockville, MD, USA), were maintained as subconfluent monolayers in DMEM (Invitrogen; Carlsbad, CA, USA) with 10% FBS (Hyclone, Logan, UT, USA) and 100 U/ml penicillin plus 100 mg/ml streptomycin (Invitrogen; Carlsbad, CA, USA). 
Cloning and mutagenesis
Full-length SUMO-1, -2 and -3 cDNAs were amplified by PCR and subsequently inserted into the pEGFP-C2 vector (Clontech, CA, USA) at the EcoR1 and BamH1 sites. To probe the functional relevance of polymerization of SUMO-2 and -3, a site-directed mutant, K11R, was prepared by the PCR amplification method using a specific mutation primer with EcoR1 and BamH1 restriction sites. To probe for the functional relevance of SUMO-2 and -3 in mammalian cells, the active and negative mutations, whose C-terminal di-glycine motif was either exposed or deleted, were created using specific primers: CG GGA TCC CG CGT CTG CTG CTG GAA (for SUMO-3) while CG GGA TCC CG CGT CTG CTG TTG GAA (for SUMO-2). The di-glycine exposed form of SUMO-2/3 was amplified with the same 3 0 -end primer: CG GGA TCC GCG TTA ACC TCC CGT CTG CTG. Mutation of Lys160Arg and Lys490Arg was conducted as described (Kamitani et al., 1998b) and verified by DNA sequencing.
SiRNA mediated depletion of SUMO-3
The siRNA sequence used for silencing of SUMO-3 corresponds to the coding region 161-179 (relative to the start codon) as described (Lou et al., 2004) . The 21-mer oligonucleotide RNA duplexes were synthesized by Dharmacon Research, Inc. (Boulder, CO, USA). In the trial experiments, different concentrations of siRNA oligonucleotides were used for different time intervals of treatment as detailed previously (Lou et al., 2004; Yao et al., 2004) . In brief, HeLa cells were synchronized and transfected with 21-mer siRNA oligonucleotides or control scramble oligonucleotide, and the efficiency of the siRNA oligonucleotide on SUMO-3 protein suppression was judged by Western blotting analysis .
Immunoprecipitation
HeLa cells were collected in phosphate-buffered saline (PBS) containing 50 mM iodoacetamide, and cell extracts were prepared in RIPA buffer containing 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM dithiothreitol, 10 mM iodoacetamide plus protease inhibitor cocktail and PMSF. Lysates were clarified by centrifugation at 16 000 Â g for 10 min at 41C. GFP-tagged SUMO-3 fusion proteins were incubated with anti-GFP monoclonal antibody bound to protein-A/G beads (Pierce, IL, USA), while PML immunoprecipitation was carried out using an affinity matrix coupled with a PML rabbit antibody (Chemicon). Beads were washed three times with RIPA buffer plus one wash with PBS followed by boiling in SDS-PAGE sample buffer for 2 min. After fractionation on SDS-PAGE, proteins were transferred onto nitrocellulose membranes and probed with mono-specific antibody against SUMO-1, -2 or -3 (Novus or Zymed; affinity purified), PML (Chemicon) and b-tubulin (Sigma), respectively. The specificity of affinity purified SUMO-1, -2 and -3 antibodies was judged by Western blotting of bacterially recombinant SUMO isoforms. Immunoreactive signals were detected with ECL kit (Pierce) and visualized by autoradiography on Kodak BioMax film.
Immunofluorescence microscopy
Cells were grown on acid-treated glass coverslips. After transfection or drug treatment, cells were washed twice with PBS and one time with PHEM (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl 2 , pH 6.9) as described (Yao et al., 2000) . Permeabilization was carried out for 1 min in PHEM buffer containing 0.1% Triton X-100 at room temperature. Pre-extracted cells were fixed in 3.7% paraformaldehyde in PHEM buffer for 10 min. After washing three times with PBS, cells were blocked with 1% BSA (Sigma) in PBS containing 0.05% Tween-20 for 30 min, and then incubated with primary antibodies for 1 h followed by secondary antibodies for 30 min. Slides were examined with a Zeiss Axiovert-200 fluorescence microscope, and images were collected and analyzed with Image-5 (Carl Zeiss, Germany). All images were processed with Adobe Photoshop 7.0 software.
Western blot
Samples were subjected to SDS-PAGE on 6-16% gradient gel and transferred onto nitrocellulose membrane. Proteins were probed by appropriate primary and secondary antibodies and detected using ECL (Pierce). The band intensity was then scanned using a Phosphoimager (Amersham Bioscience).
